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Insulin (MW 5807.6), Tetraethylorthosilicate (TEOS), Tetramethoxyorthosilicate (TMOS), trimethylchlorosilane (TMCS), 
EO20PO70EO20 [donated as P123, where EO is poly-(ethylene oxide) and PO is poly (propylene oxide)], α-cyano-4-hydroxycinnamic 
acid (CHCA, 99%), 3-Aminopropyl(diethoxy)methylsilane(APDEMS), 3-aminopropyltriethoxysilane (APTES), horse serum, sodium 
sulfate (Na2SO4), 2-(N-morpholino)ethanesulfonic acid (MES, pH 5.5),  N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) and N-Hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich. Hydrochloric acid (HCl) and ethanol 
were received from ChemSupply. Toluene, Acetonitrile (ACN, 99.9%) and trifluoroacetic acid (TFA, 99.8%) were purchased from 
Merck. COOH-IBA (COOH-ACAGGGGTGTGGGGACAGGGGTGTGGGG) was ordered from Thermo Fisher Scientific. Human 
insulin ELISA kit was purchased from Life Technologies (Australia Pty Ltd). All reagents were used as received without further 
purification. Deionized water (DI water) (18.2 mV cm) used for all experiments was obtained from a Milli-Q system (Millipore, Bedford, 
MA). 
1.2 Materials Synthesis
Silica materials (denoted SBA-15 and MOSF) were synthesized using modified literature methods, and the experimental processes 
are given as follows:
For SBA-15, P123 (1.0g) was dissolved in 2M HCl (30g) solution at 38 °C. Then TEOS (2.08g) was added into the homogeneous 
solution under stirring at 38 °C for 24h. The resulting white precipitate was filtered and mixed with 40g of deionized water and the pH 
was adjusted to 1.65 using 1 M HCl. The reaction mixture was heated at 130 °C for another 24h. The as-synthesized SBA-15 was 
filtered and dried at room temperature. Calcination was performed in furnace at 550 °C for 5h to completely eliminate the surfactants. 
1, 2
For MOSF, it includes a synthesis of MOSF and a further modification of –CH3. For MOSF, At 35 oC, 1.0 g of P123 and 1.7 g of 
Na2SO4 (0.4 M) were dissolved in 30 g of pH=5.0 NaAc-HAc buffer solution (Ct=0.02 M, where Ct=CNaAc + CHAc) to form a 
homogenous solution under stirring. To this mixture solution, 1.52 g of TMOS was added under stirring for 5 minutes. The resultant 
mixture was kept at static condition for 24 h and then hydrothermally treated at 100 oC for another 24 h. The product was filtered and 
washed repeatedly with water to remove inorganic salts, and then dried at room temperature. The final MOSF products were 
obtained by calcination at 550 oC for 5 h.3 
1.3 Methyl modification
1 g of silica was added into 30 ml of 5 wt % TMCS-toluene solution with stirring at 70 °C, 24h. The mixture was centrifuged and 
extensively washed with ethanol to rinse away any residual chemicals. Finally, the powder was dried at 50 °C.4 
1.4 Amino modification
1 g of SBA-15 was suspended in 30 ml of 4mmol APTES-toluene solution, and the mixture was refluxed at 110 °C for 20 h. The 
products were centrifuged and washed with ethanol for 3 times. In the last step, the powder was dried room temperature overnight.5
1.5 Co-modification of IBA and CH3
1 g of SBA-15 was dispersed in 30 ml of 4 mmol APDEMS-toluene solution. The mixture was stirring at 70 °C overnight. After 
washing with ethanol for 3 times, the product was dried at room temperature. SBA-15 with modifications of both CH3 and NH2 is 
denoted SBA-15-CH3-NH2.
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For the nanoparticles with co-modification only on the outer surface [SBA-15-CH3-IBA (out)]: the as-synthesized SBA-15 (with 
surfactant) was applied to the reaction with APDEMS directly. With the existence of surfactant, the CH3 and NH2 were only modified 
on the outer surface of SBA-15. Then, the surfactant of modified nanoparticles was removed by extraction with methanol-HCl (128 ml 
methanol and 8ml HCl) under stirring for 48 h. The product was dried at room temperature and ready for the conjugation with IBA. 
For the conjugation of IBA:  100 mg of SBA-15-CH3-NH2 was suspended in 25 ml MES buffer and sonicated for a few minute to have 
a well-dispersed and homogenous solution. To this solution, EDC (60 mg dissolved in 25 ml of MES buffer) and NHS (160 mg 
dissolved in 25 ml of MES buffer) were added, followed by 25 nmol of COOH-IBA (100µM in DNA-free H2O). The reaction was 
conducted at room temperature with gentle shaking for 3 h. After 3 times washing with phosphate buffered saline buffer (PBS buffer, 
pH7.2), the SBA-15-CH3-IBA conjugates were stored at 4°C and ready for use.  
1.6 Materials characterization
Small-angle X-ray scattering (SAXS) was performed using an Anton-Parr SAXSess small-angle X-ray scattering system (Cu KR 
radiation, 35kV, 30 mA). The samples were placed onto the transparent tape as a thin layer and mounted onto the sample holder, 
analysed for the scattering peaks, and for background/blank only tape is mounted onto the sample holder. All the samples were 
analysed using following parameters: Number of exposure to average per experiment (scan rate) = 1000; Exposure time=0.2 
seconds; Width of detection area= 30 mm; Wavelength =0.1542 nm; Sample detector distance = 309 nm.
Nitrogen-sorption isotherms of the samples were obtained by a Micromeritics Tristar II 3020 system at 77 K. Before the 
measurements, about 50 mg of each sample was weighted and degassed at 100 °C for at least 8 h in vacuum. After degassing, the 
samples were weighted again to get the accurate weight and then transferred to the Tristar system for testing. 
Fourier transform infrared (FTIR) spectra were collected with ThermoNicolet Nexus 6700 FTIR spectrometer equipped with Diamond 
ATR (attenuated total reflection) Crystal. The platform and diamond were cleaned with ethanol before placing each sample. For each 
spectrum, 128 scans were collected at a resolution of 4 cm-1 over the range 500–4000cm-1. 
Transmission electron microscopy (TEM) images were directly taken with a JEOL 1010 microscope operated at 100 kV. Samples 
were dispersing in ethanol before coating on Cu grids covered with carbon films. After evaporating the ethanol, the Cu grids were 
ready for TEM testing.
 
ζ potential measurements were carried out at 25 °C using a Zetasizer Nano-ZS from Malvern Instruments. The samples were 
dispersed
in Milli-Q water before testing.
X-ray photoelectron spectroscopy (XPS) measurements were performed with a Kratos Axis Ultra X-ray photoelectron spectrometer 
(Perkin-Elmer). All spectra were acquired at a basic pressure of 2 × 10−7 Torr with Mg Kα excitation at 15 kV. All the results were 
analysed using the CasaXPS software and corrected by referencing the C 1s peak at 284.8 eV.
1.7 Enrichment of insulin in serum 
The insulin serum solution (10% horse serum) was prepared freshly every time before experimentation with a stepwise dilution 
method. Firstly, 5 µl (10 µg/ µl) MOSF-CH3 was added into the insulin serum sample (500 µl) for the first step purification. After 5 min 
of stirring and 10 min of centrifugation, the supernatant was transferred to another Eppendorf tube for enrichment, and the sediment 
was spotted onto the MALDI MPT 384 plate and mixed with 1 µl CHCA solution before test. In the next step, 1 µl (10 µg/ µl) SBA-15-
CH3-IBA was added into the purified solution for further enrichment. Stirring (5 min) and centrifugation (10 min) were conducted 
before removing the supernatant, sediment was finally mixed with CHCA for MS analysis.
     All the samples were analyzed on a Bruker Autoflex TOF/TOF III Smart beam. The mass spectra were obtained in the LP-PepMix 
mode via an accumulation of 200 laser shots at 10 different sites under a laser intensity of 39% for data collection and calibrated. 
Three standard peptides, Angiotensin II (Mw = 1046.5 Da), ACTH-Clip (Mw = 2465.2 Da) and Somatostatin 28 (Mw 3147.5 Da) were 
used for calibration purposes to reduce variability.
1.8 Pre-enrichment enhanced ELISA 
The standard insulin solutions in a low concentration range (0.005 ~ 0.00025 ng ml-1) were prepared freshly by stepwise diluting the 
standard solution #1 in the ELISA kit (containing 0.2 ng ml-1 of insulin in human serum). For these intact insulin solutions, 50 µl of 
each was kept as the control group. For the insulin pre-enrichment, 30 µl (10 mg/ml) of MOSF-CH3 was added into each sample (5 
ml) for the first step purification. After stirring and centrifugation, the supernatant was separated and transferred for the second 
enrichment step. Then, 10 µl (10 mg/ml) SBA-15-CH3-IBA was added to enrich insulin from the purified supernatant with 5 mins 
mixing. After centrifugation, the supernatant was removed and 2 ml of 80% ACN(0.1%TFA) was added to the sediment for elution. In 
the next step, the eluted solution was centrifuged and the supernatant with insulin was transfered to another tube for vacuum drying 
at 45৹C overnight. The sample was ready for ELISA test after redissolving with 50 µl DI water. 
ELISA test was conducted following the instruction in the commercial kit, the mechamism is showing in Figure S6. Typically, 50 µl of 
each standards/control/samples was added into the wells together with 50 µl anti-insulin HRP, incubating for 30 min at room 
temperature. The liquid was decanted thoroughly and the walls were washed 3 times with the diluted wash solution before adding 
100 µl stabilized chromogen. After 15 min, 100 µl of stop solution was added and the plate was measured by reading the absorbance 
at 450 nm using a Synergy HT microplate reader within 1 h. All the standards/control/samples were run in duplicate.
To test the recovery rate, a fix amount of standard (0.005 ng) was spiked to sample 1 with 0.01 ng insulin, and the amount of spikd 
standard plus sample 1 is sample 2. Then, both sample 1 and 2 were pre-treated by the designed combo-pore-CH3-IBA approach 
following with ELISA test, and the results were calculated according to the low concentration standard curve (Figure 3b). 
Theoratically, the difference of insulin amount between sample 1 and 2 is the spiked amount (0.005 ng). Thus, the accurancy of our 
combo-pore-CH3-IBA enhanced ELISA is represented by the ratio (recovery rate) of testing spiked standard to 0.005 ng (theoratical 
spiked amount). 
2. Table and Figures
Table S1. Methods and LOD of insulin detection in references
Method Quantitative/Qualitative LOD (ng ml-1) Ref.no
RIAs Quantitative 10.4 (Cerebrospinal fluid) 6
Human Insulin-Enzyme Amplified Sensitivity Immunoassay (EASIA)
SPE-Electrospray LC-MS with bovine insulin as internal standard
SPE-IAC-LC-MS/MS
Micro-SPE with molecularly imprinted polymer-sensor 























Aptamer-MALDI-TOF MS Qualitative 20 (Serum) 15
Photoluminescence (PL) emission of aptamer-coated SWNTs











Fig. S1 SAXS patterns of a) SBA-15; b) SBA-15-NH2; c) SBA-15-CH3-NH2 and d) SBA-15-CH3-NH2 (out). 
Fig. S2  TEM images of (a) SBA-15, (b) SBA-15-CH3-NH2, c) SBA-15-NH2 and (d) SBA-15-CH3-NH2 (out).
Fig. S3 Nitrogen adsorption-desorption isotherms and pore size distribution curves of SBA-15 with& without modifications. 
Fig. S4  FTIR spectra of SBA-15, SBA-15-NH2, SBA-15-CH3-NH2 and SBA-15-CH3-NH2 (out). Black arrows show the peaks of -CH3 group.
Fig. S5 MS spectra obtained from a)10ng ml-1 human insulin (in horse serum); b) 0.05 ng ml-1 human insulin (in horse serum) with pre-
treatment by designed SBA15-CH3-IBA; c)1ng ml-1 human insulin (in horse serum) with pre-treatment by SBA15-IBA; d) 0.5 ng ml-1 human 
insulin in horse serum with pre-treatment by SBA15-CH3-IBA (out); *stands for the single charged molecular ion peak, ** stands for the double 
charged molecular ion peak of human insulin molecule.
Scheme S1. Illustration showing the mechanism of sandwich-like ELISA.
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